Boston Scientific Corporation$47.23CAH · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $222.58B | $226.83B | $204.98B | $181.33B | $162.47B | $152.92B | $145.53B | $136.81B |
| Cost of Revenue | $214.41B | $219.41B | $198.10B | $174.84B | $155.69B | $146.05B | $138.70B | $129.63B |
| Gross Profit | $8.17B | $7.41B | $6.87B | $6.48B | $6.78B | $6.87B | $6.83B | $7.18B |
| Selling, General & Administrative | $5.38B | $5.00B | $4.80B | $4.51B | $4.53B | $4.57B | $4.48B | $4.60B |
| Operating Income | $2.27B | $1.24B | $752.00M | -$607.00M | $472.00M | -$4.10B | $2.06B | $126.00M |
| Interest Expense | $215.00M | $51.00M | $84.00M | $147.00M | $180.00M | $238.00M | $294.00M | $329.00M |
| Other Income / (Expense) | $41.00M | $9.00M | -$5.00M | -$22.00M | $47.00M | $1.00M | -$15.00M | -$23.00M |
| Income Before Taxes | $2.10B | $1.20B | $663.00M | -$784.00M | $323.00M | -$3.77B | $1.75B | -$228.00M |
| Provision for Income Taxes | $532.00M | $348.00M | $332.00M | $153.00M | -$289.00M | -$79.00M | $386.00M | -$487.00M |
| Net Income | $1.56B | $852.00M | $330.00M | -$938.00M | $611.00M | -$3.70B | $1.36B | $256.00M |
| Basic EPS | $6.48 | $3.48 | $1.27 | -$3.37 | $2.09 | -$12.61 | $4.55 | $0.82 |
| Diluted EPS | $6.45 | $3.45 | $1.26 | -$3.37 | $2.08 | -$12.61 | $4.53 | $0.81 |
| Basic Shares Outstanding | 241.00M | 245.00M | 261.00M | 279.00M | 292.00M | 293.00M | 300.00M | 313.00M |
| Diluted Shares Outstanding | 242.00M | 247.00M | 262.00M | 279.00M | 294.00M | 293.00M | 301.00M | 315.00M |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Jun 2026 | $10.77 | $10.74 | $10.81 | 9 | ↑2 ↓0 |
| Jun 2027 | $12.04 | $11.67 | $12.41 | 9 | ↑2 ↓0 |
| Jun 2028 | $13.48 | $13.34 | $13.57 | 3 | ↑0 ↓0 |
| Jun 2029 | $14.79 | $14.59 | $14.92 | 3 | ↑0 ↓0 |
